Anti-VEGF and anti-angiopoietin treatment leading to vessel normalization, reduce hypoxia, induce TAM repolarization and improve CTL, NK cell infiltration.98 Several drugs are used clinically targeting TAM such as trabectedin reduce TAM survival and alemtuzumab eliminates TAMs by targeting a TAM surface protein.99 Therefore, more investigation are required to assess the elevated ratio of M1-like macrophage to M2-like macrophage to identify tumor prognosis and prevent tumor progression. The gene discussed is VEGFA; the disease is neoplasm.